Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma

by Vandana Singh, Benzinga Editor

August 30, 2021 10:13 AM | 1 min read | Make a Comment

The FDA has cleared Poseida Therapeutics Inc PSTX Investigational New Drug (IND) application for P-BCMA-ALLO1, a fully allogeneic CAR-T product candidate for relapsed/refractory multiple myeloma.
The Phase 1 study will assess safety, tolerability, and response. The study protocol allows for exploration of additional dosing regimens, including re-dosing, once initial safety has been established.
Poseida is actively focused on opening clinical sites to begin dosing later this year.
Related content: Benzinga's Full FDA Calendar
Price Action: PSTX stock is up 5% at $10.40 during the market session on the last check Monday.

Posted In: Biotech Long Ideas News Health Care Small Cap FDA Movers Trading Ideas General Briefs multiple myeloma Phase 1 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.